VIVUS Appoints Robert N. Wilson to Board of Directors
MOUNTAIN VIEW, Calif., April 30, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS) today announced the appointment of Robert N. Wilson, chairman of
Mevion Medical Systems and former vice chairman of the Board of Directors of
Johnson & Johnson, to its Board of Directors effective April 26, 2013. Mr.
Wilson served in several roles at Johnson & Johnson, including the Executive
Committee from 1983 through 2003 and vice chairman of the Board of Directors
from 1988 through 2003. Mr. Wilson played a key role in the rapid growth of
the pharmaceutical, device and diagnostic businesses within Johnson &
Johnson.Mr. Wilson was also chairman of Caxton Health Holdings from 2004
through 2007, focusing on pharmaceutical and health technology investments.
"We are pleased to welcome a new, independent director of Bob's caliber to the
VIVUS Board of Directors," said Mark B. Logan, chairman of the Board of
Directors of VIVUS. "Bob is a highly qualified and experienced professional
with proven leadership in the healthcare industry and invaluable expertise in
pharmaceutical development, brand building and operations. We look forward to
adding his unique perspective as we continue to successfully execute our
commercialization strategy for Qsymia for the benefit of all VIVUS
Mr. Wilson is also a director of Hess Corporation, an explorer and producer of
oil and gas, the Charles Schwab Corporation, a financial services company, and
Synta Pharmaceuticals, a research-based pharmaceutical company with a focus in
"I am excited to join the Board of VIVUS, a company with significant
opportunities to fully commercialize its wholly-owned, next-generation
therapies that address unmet needs of physicians and their patients," said Mr.
Wilson."I look forward to sharing my experience and working closely with my
fellow VIVUS directors, each of whom is a proven and respected business
leader, to help enhance the value of the company."
VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity, sleep
apnea, diabetes and sexual health. For more information about the company,
please visit www.vivus.com.
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS' Form
10-K for the year ending December 31, 2012, and periodic reports filed with
the Securities and Exchange Commission.
Important Additional Information
VIVUS, its directors and certain of its executive officers may be deemed to be
participants in the solicitation of proxies from VIVUS stockholders in
connection with the matters to be considered at VIVUS's 2013 Annual Meeting of
Stockholders. VIVUS intends to file a proxy statement with the U.S. Securities
and Exchange Commission (the "SEC") in connection with any such solicitation
of proxies from VIVUS stockholders. INVESTORS AND STOCKHOLDERS ARE STRONGLY
ENCOURAGED TO READ ANY SUCH PROXY STATEMENT AND ACCOMPANYING PROXY CARD AND
OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Information
regarding the identity of potential participants, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in the proxy
statement and other materials to be filed with the SEC in connection with
VIVUS's 2013 Annual Meeting of Stockholders. Information regarding the direct
and indirect beneficial ownership of VIVUS's directors and executive officers
in VIVUS securities is included in their SEC filings on Forms 3, 4 and 5, and
additional information can also be found in VIVUS's Annual Report on Form 10-K
for the year ended December 31, 2012, filed with the SEC on February 26, 2013,
and in VIVUS's definitive proxy statement on Schedule 14A in connection with
VIVUS's 2012 Annual Meeting of Stockholders, filed with the SEC on April 25,
2012. Stockholders will be able to obtain any proxy statement, any amendments
or supplements to the proxy statement and other documents filed by VIVUS with
the SEC for no charge at the SEC's website at www.sec.gov. Copies will also be
available at no charge at the Investor Relations section of VIVUS's corporate
website at www.vivus.com.
CONTACT: VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
Dana B. Shinbaum
The Trout Group
Morrow & Co., LLC
Joseph J. Mills
Joele Frank, Wilkinson Brimmer Katcher
Matthew Sherman | Jennifer Beugelmans
email@example.com | firstname.lastname@example.org
212-235-2665 | 212-895-8692
Press spacebar to pause and continue. Press esc to stop.